Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,075Revenue (TTM) $M166Net Margin (%)-43.9Altman Z-Score-7.1
Enterprise Value $M1,146EPS (TTM) $-0.3Operating Margin %-30.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-36.5Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-20.4Quick Ratio1.3Cash flow > EarningsY
Price/Sales6.55-y EBITDA Growth Rate %-16.9Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-41.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M271ROIC % (ttm)-1,005.7Gross Margin Increase y-yY

Gurus Latest Trades with AMRN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AMRN is held by these investors:



AMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kennedy Joseph TGeneral Counsel 2018-01-17Sell51,106$4.1-3.17view
Ketchum Steven BChief Scientific Officer 2018-01-11Sell2,612$4.4-9.77view
Ketchum Steven BChief Scientific Officer 2018-01-05Sell64,683$4.4-9.77view
Ketchum Steven BChief Scientific Officer 2018-01-02Sell128,257$4.25-6.59view
THERO JOHN FPresident and CEO 2017-11-30Buy10,000$3.2422.53view
Ketchum Steven BChief Scientific Officer 2017-10-05Sell63,479$3.4814.08view
Kennedy Joseph TGeneral Counsel 2017-07-03Sell307,911$4-0.75view
Kennedy Joseph TGeneral Counsel 2016-11-09Sell122,358$3.0430.59view
THERO JOHN FPresident and CEO 2016-02-01Buy25,000$1.37189.78view
THERO JOHN FPresident and CEO 2015-08-11Buy20,000$2.3568.94view

Press Releases about AMRN :

Quarterly/Annual Reports about AMRN:

News about AMRN:

Articles On GuruFocus.com
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook Jan 04 2018 
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2 Dec 19 2017 
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2 Dec 19 2017 
Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco Dec 18 2017 
Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco Dec 18 2017 
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associ Nov 14 2017 
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associ Nov 14 2017 
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Mark Nov 13 2017 
Amarin to Present at the Jefferies London Healthcare Conference Nov 07 2017 
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 Oct 25 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK